Compare Ascendis Pharma A/S (ASND) vs RLX Technology Inc (RLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs RLX Technology Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while RLX Technology Inc trades at $1.96 (market cap $2.38B). The key difference: Ascendis Pharma A/S is far larger — about 7.5× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.13% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | RLX | |
|---|---|---|
Market Cap | $17.74B | $2.38B |
Sector | Health | Technology |
52-Week High | $277.18 | $2.73 |
52-Week Low | $163.32 | $1.79 |
Enterprise Value | $18.11B | $1.02B |
Dividend Yield | — | 5.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
RLX trades at $1.95, down 2.01% today, amid mixed technical signals with a neutral overall outlook. The company reported strong 2025 fundamentals with $3.62B revenue and $922M net income, though recent quarterly EPS results have missed expectations. Analyst coverage is limited to a single hold rating, while news highlights international expansion and a cash-rich, debt-free balance sheet.
The outlook is cautious due to earnings misses and a neutral technical stance, but the company's profitability, growth potential in the vaping industry, and solid financial health present a long-term opportunity. Key risks include regulatory pressures and competitive threats in the e-cigarette market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
